Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

Could a new drug change pancreatic cancer treatment?

Researchers at Silexion Therapeutics have made significant strides toward advancing a new treatment for pancreatic cancer. Their drug, SIL204, is designed to target a mutated gene called KRAS, which is commonly associated with various cancers. The company has begun manufacturing the drug in preparation for an upcoming Phase 2/3 clinical trial that aims to evaluate its effectiveness in patients with locally advanced pancreatic cancer.

This development is crucial for anyone concerned about cancer, particularly pancreatic cancer, which is known for its poor prognosis. If successful, SIL204 could offer a new treatment option that combines standard chemotherapy with this innovative therapy, potentially improving outcomes for people diagnosed with this aggressive disease. The trial will assess both the safety and effectiveness of SIL204, providing hope for better management of pancreatic cancer.

Currently, the research is in the early stages, with the Phase 2/3 trial set to begin soon after receiving ethical approval from a leading Israeli oncology center. While the initial findings from earlier studies are promising, it’s important to note that this is not yet a proven treatment for humans. The trial will include a safety run-in segment followed by a randomized cohort, which will help gather more data on how well the drug works in real patients.

For those interested in the latest advancements in cancer treatments, keeping an eye on the results of this trial could be worthwhile. While SIL204 is not available yet, it represents a step forward in the ongoing battle against pancreatic cancer, and its progress may lead to new strategies for improving patient care in the future.

Source: globenewswire.com